Anindita Nayak
Bhubaneswar, 27 Jan 2026
Syngene International’s stock price lost close to 19% in last six trading sessions after the company posted weak set of Q3FY26 numbers. The company reported a net profit decline of 86.6% year-on-year for the third quarter of the financial year 2026, driven mainly by a one-time exceptional charge associated with regulatory changes.
Here is a snapshot of its Q3FY26 Performance:
| Particulars | Q3 FY26 | Rise/Fall (YoY) |
| Revenue from Operations | ₹8,34.4 crore | 4.9% ↓ |
| Gross profit Margin (%) | 15.49% | 15.19% ↓ |
| Operating EBITDA Margin | 23% | 7% ↓ |
| Net Income (PAT) | ₹16.5 crore | 86.6% ↓ |
| Diluted EPS | ₹0.41 | 86.6% ↓ |
Other significant performance:
| Metric | Q3 FY26 (₹ Crore) | Rise/Fall YoY |
| Consolidated Revenue | ₹917 | 3% ↓ |
| Capitalized Biologics Assets | ₹344 | 100% ↑ |
Disclaimer: This information is for educational purposes only. Please consult your financial advisor before investing in stocks.
